Home › Research › Inflammation and the immune system
Can the herpes zoster vaccination be a strategy against dementia?
Yanan Ma, Kenji Karako, Peipei Song, Ying Xia. Drug Discoveries & Therapeutics, 2025-04-30
Topic: Risk, prevention and care in population studies
Plain-language summary
Herpes Zoster (HZ), caused by the reactivation of the varicella-zoster virus (VZV), is a common infectious disease. Recent studies suggest a potential association between HZ and the development of dementia, particularly Alzheimer's disease and other neurodegenerative disorders. Epidemiological evidence indicates that HZ infection, especially in individuals with central nervous system involvement, may increase the risk of dementia. Pathologically, VZV may contribute to neuronal dysfunction and degeneration by inducing chronic neuroinflammation, infection-related cerebrovascular lesions, and direct central nervous system toxicity. HZ vaccines, particularly novel recombinant subunit vaccines (e.g., Shingrix), not only effectively prevent HZ but may also confer cognitive protection through mechanisms such as "trained immunity" activation and anti-inflammatory response modulation. Multiple natural experiments and retrospective cohort studies have found that HZ vaccination is significantly associated with a reduced risk of dementia, with particularly pronounced protective effects in women and older adults. Although most evidence currently stems from observational studies and is subject to potential confounding factors, the biological plausibility and consistent findings support the potential of HZ vaccination as an adjunctive strategy for dementia prevention. Future prospective randomized controlled trials are needed to further clarify the causal relationship and underlying neuroimmune mechanisms, providing a stronger evidence base for establishing scientific vaccination strategies for older adults and dementia prevention systems.
What this study adds
Evidence grade: High
This is a follow-up (cohort) study. Observational studies and natural experiments suggest that herpes zoster vaccination is linked to a lower risk of dementia, especially in women and older adults. The evidence comes from observational data that can be affected by confounding factors, so it does not prove that vaccination prevents dementia.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Ma, Y., Karako, K., Song, P., & Xia, Y. (2025). Can the herpes zoster vaccination be a strategy against dementia? Drug Discoveries & Therapeutics. https://doi.org/10.5582/ddt.2025.01032
Vancouver
Ma Y, Karako K, Song P, Xia Y. Can the herpes zoster vaccination be a strategy against dementia? Drug Discoveries & Therapeutics. 2025. doi:10.5582/ddt.2025.01032. PMID: 40350295.
BibTeX
@article{ma2025-40350295,
author = {Ma, Yanan and Karako, Kenji and Song, Peipei and Xia, Ying},
title = {{Can the herpes zoster vaccination be a strategy against dementia?}},
journal = {Drug Discoveries \& Therapeutics},
year = {2025},
doi = {10.5582/ddt.2025.01032},
pmid = {40350295},
url = {https://doi.org/10.5582/ddt.2025.01032}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Epidemiological evidence indicates that HZ infection, especially in individuals with central nervous system involvement, may increase the risk of dementia.
- Multiple natural experiments and retrospective cohort studies have found that HZ vaccination is significantly associated with a reduced risk of dementia, with particularly pronounced protective effects in women and older adults.
Why it matters
Observational studies and natural experiments suggest that herpes zoster vaccination is linked to a lower risk of dementia, especially in women and older adults. The evidence comes from observational data that can be affected by confounding factors, so it does not prove that vaccination prevents dementia.
Study details
- Study designcohort study
- Evidence strengthHigh
How this study scored 48/100
Published in a peer-reviewed journal, and it is a cohort study following people over time. Scored zero for sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Drug Discoveries & Therapeutics) |
| Journal's citation record | 0 / 4 | Drug Discoveries & Therapeutics: journal h-index 43 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 9 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 3.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 5.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 9 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Ying Xia: h-index 7 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | The University of Tokyo: institution h-index 1,463 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40350295) |
| Free to read | 2 / 2 | Free to read |
| Total | 48 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.5582/ddt.2025.01032
- PubMed: 40350295
- Original source →
- Free full text: Drug Discoveries & Therapeutics →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Inflammation and the immune system from nearby years
Also tagged “prevalence”
1,224 studies in the library carry the topic tag “prevalence”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,224 tagged studies.